Urinary And Reproductive Tract Cancers In Dogs And Cats

These cancers affect the kidneys, bladder, urethra, prostate, uterus, ovaries, and testes, and can significantly impact a pet’s comfort and quality of life. In dogs, transitional cell carcinoma (TCC) of the bladder and urethra is the most common and highly invasive urinary tract cancer. Other types include prostatic carcinoma in older males and renal carcinoma or sarcomas in the kidneys. In cats, bladder tumours are less frequent, but renal lymphoma and carcinoma occur. Reproductive cancers such as ovarian carcinoma, uterine tumours, and testicular tumours are also seen, particularly in intact animals.

Common symptoms include blood in the urine, straining or difficulty urinating, frequent urination, or incontinence. Abdominal or perineal swelling may be present, and pets with prostate cancer can show back pain or lameness due to tumour spread. In advanced disease, signs such as weight loss, lethargy, and general unwellness are common. Because these symptoms can mimic urinary infections or inflammation, thorough diagnostics are essential.

Diagnosis usually begins with urinalysis, urine cytology, and imaging such as ultrasound or CT to assess the urinary tract and nearby organs. In some cases, cystoscopy or biopsy is used for definitive diagnosis. However, traditional imaging may not always reveal hidden metastases or distinguish between inflammation and malignancy. PET-CT provides a clearer, more comprehensive understanding of the disease.

PET-CT combines detailed anatomical imaging with metabolic mapping, allowing vets to detect cancer activity throughout the body. It identifies metastases in lymph nodes, lungs, bones, or abdominal organs that might be missed on ultrasound or CT. PET-CT also distinguishes malignant lesions from benign inflammation or tissue overgrowth, especially in the bladder and prostate, giving a more accurate picture of the disease.

PET-CT defines tumour boundaries for surgery or radiation, ensuring treatments target active cancer while sparing healthy tissue. It can detect early metabolic changes during chemotherapy, radiation, or targeted therapy — often before size changes are visible — helping vets assess treatment effectiveness. Uptake intensity patterns also provide insight into tumour aggressiveness and prognosis, supporting well-informed discussions with pet owners.

Urinary and reproductive tract cancers can be distressing for owners because they affect basic functions like urination and comfort. PET Theranostics supports veterinary teams with the most advanced diagnostic imaging available, offering whole-body insight that ensures no disease is missed. This clarity helps vets plan treatment confidently and communicate realistic expectations with compassion and precision.